Breast cancer immunophenotype and its relationship with haematopoiesis

Background. The applying of immunotherapeutic approaches in cancer treatment requires a deep and comprehensive understanding of the tumor biological characteristics. In this regard, the study of the tumor immunophenotype is one of the leading scientific directions. The major histocompatibility compl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Denis A. Ryabchikov, Svetlana V. Chulkova, Farhad A. Shamilov, Nail V. Chanturia, Sergey D. Zheltikov, Nikolai N. Tupitsyn
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	luminal breast cancer immunophenotype hla-i hla-ii cd71 bone marrow hematopoiesis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a40f4ec5f398415db2bcda020a9a7bda
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a40f4ec5f398415db2bcda020a9a7bda
record_format	dspace
spelling	oai:doaj.org-article:a40f4ec5f398415db2bcda020a9a7bda2021-11-30T16:55:01ZBreast cancer immunophenotype and its relationship with haematopoiesis1815-14341815-144210.26442/18151434.2021.2.200958https://doaj.org/article/a40f4ec5f398415db2bcda020a9a7bda2021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/75935/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Background. The applying of immunotherapeutic approaches in cancer treatment requires a deep and comprehensive understanding of the tumor biological characteristics. In this regard, the study of the tumor immunophenotype is one of the leading scientific directions. The major histocompatibility complex molecules are considered to be the promising markers of the immunotherapy effectiveness prediciton. Aim. To research tumor immunophenotype in different molecular subtypes of breast cancer (BC). Materials and methods. The study included 99 patients with BC. Luminal cancer 84.8% (n=83), Erb-B2 overexpressing (HER2+) subtype 5.0% of cases (n=5), triple-negative BC 10.2% (n=10). Stages: T1 (51.5%), T2 (44.4%), T3 (2.0%). Lymph node metastases (N+) were present in 39.4% (n=39) of cases. Grade of malignancy: 80.8% (G2). Samples of tumor tissue and bone marrow were examined. Immunophenotyping of the tumor was carried out on cryostat sections by the method of immunofluorescense. Antibodies to HLA-I, HLA-DR, CD71 were used and were directly conjugated to fluorochromes PE, FITC, PE-Cy5. The bone marrow was examined by a morphological method using light microscopy. Statistical data processing was performed using the IBM-SPSS statistics v2.1. Results. In 50.8% (31/61) cases of luminal BC (LBC), the HLA-I molecule is absent on the membrane or is expressed by single tumor cells. A decrease in HLA-I expression levels in the luminal subtype was combined with the absence of HLA-DR antigens, which was found in 63.1% of cases. A higher frequency of HLA-I expression is observed in the Erb-B2 overexpressing BC, the differences are insignificant. Expression of CD71 was defected in 67.8% (40/59) of the studied samples of LBC. CD71 was expressed on the surface of most tumor cells (70%) in triple-negative BC. There were no statistically significant differences between the studied molecular subtypes of BC. Analysis of the luminal subtypes revealed that CD71 expression was observed much more often in luminal B subtype: 76.5% (n=26) and 75% (n=3) versus 52.4% (n=11). HLA-I expressing luminal cancer were characterized by higher levels of erythroid precursors (polychromatophilic normoblasts 9.00.9 and 5.80.8%, p=0.0017; oxyphilic normoblasts (7.90.7 and 5.30.6%, p=0.008), an increase in the amount of erythroid germ cells (17.71.5 and 11.61.5%, р=0.009) and an increased content of myelokaryocytes (93.117.1 thousand/l versus 57.39.0 thousand/l, p=0.083). Conclusion. In LBC a decrease in the expression levels of HLA-I class molecules was noted in combination with the absence of HLA-DR antigens on the membrane of tumor cells, which was observed in more than half of the analyzed samples. The frequency of expression in triple-negative cancer is higher than in the luminal subtype. There were no statistically significant differences between molecular subtypes by the level of expression of HLA-I and II class molecules. Transferrin receptor expression has been reported in most cases of triple-negative BC subtype. The interconnection between the expression of HLA-I histocompatibility molecules and hematopoetic parameters in LBC has been established.Denis A. RyabchikovSvetlana V. ChulkovaFarhad A. ShamilovNail V. ChanturiaSergey D. ZheltikovNikolai N. TupitsynIP Habib O.N.articleluminal breast cancerimmunophenotypehla-ihla-iicd71bone marrowhematopoiesisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 275-279 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	luminal breast cancer immunophenotype hla-i hla-ii cd71 bone marrow hematopoiesis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	luminal breast cancer immunophenotype hla-i hla-ii cd71 bone marrow hematopoiesis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Denis A. Ryabchikov Svetlana V. Chulkova Farhad A. Shamilov Nail V. Chanturia Sergey D. Zheltikov Nikolai N. Tupitsyn Breast cancer immunophenotype and its relationship with haematopoiesis
description	Background. The applying of immunotherapeutic approaches in cancer treatment requires a deep and comprehensive understanding of the tumor biological characteristics. In this regard, the study of the tumor immunophenotype is one of the leading scientific directions. The major histocompatibility complex molecules are considered to be the promising markers of the immunotherapy effectiveness prediciton. Aim. To research tumor immunophenotype in different molecular subtypes of breast cancer (BC). Materials and methods. The study included 99 patients with BC. Luminal cancer 84.8% (n=83), Erb-B2 overexpressing (HER2+) subtype 5.0% of cases (n=5), triple-negative BC 10.2% (n=10). Stages: T1 (51.5%), T2 (44.4%), T3 (2.0%). Lymph node metastases (N+) were present in 39.4% (n=39) of cases. Grade of malignancy: 80.8% (G2). Samples of tumor tissue and bone marrow were examined. Immunophenotyping of the tumor was carried out on cryostat sections by the method of immunofluorescense. Antibodies to HLA-I, HLA-DR, CD71 were used and were directly conjugated to fluorochromes PE, FITC, PE-Cy5. The bone marrow was examined by a morphological method using light microscopy. Statistical data processing was performed using the IBM-SPSS statistics v2.1. Results. In 50.8% (31/61) cases of luminal BC (LBC), the HLA-I molecule is absent on the membrane or is expressed by single tumor cells. A decrease in HLA-I expression levels in the luminal subtype was combined with the absence of HLA-DR antigens, which was found in 63.1% of cases. A higher frequency of HLA-I expression is observed in the Erb-B2 overexpressing BC, the differences are insignificant. Expression of CD71 was defected in 67.8% (40/59) of the studied samples of LBC. CD71 was expressed on the surface of most tumor cells (70%) in triple-negative BC. There were no statistically significant differences between the studied molecular subtypes of BC. Analysis of the luminal subtypes revealed that CD71 expression was observed much more often in luminal B subtype: 76.5% (n=26) and 75% (n=3) versus 52.4% (n=11). HLA-I expressing luminal cancer were characterized by higher levels of erythroid precursors (polychromatophilic normoblasts 9.00.9 and 5.80.8%, p=0.0017; oxyphilic normoblasts (7.90.7 and 5.30.6%, p=0.008), an increase in the amount of erythroid germ cells (17.71.5 and 11.61.5%, р=0.009) and an increased content of myelokaryocytes (93.117.1 thousand/l versus 57.39.0 thousand/l, p=0.083). Conclusion. In LBC a decrease in the expression levels of HLA-I class molecules was noted in combination with the absence of HLA-DR antigens on the membrane of tumor cells, which was observed in more than half of the analyzed samples. The frequency of expression in triple-negative cancer is higher than in the luminal subtype. There were no statistically significant differences between molecular subtypes by the level of expression of HLA-I and II class molecules. Transferrin receptor expression has been reported in most cases of triple-negative BC subtype. The interconnection between the expression of HLA-I histocompatibility molecules and hematopoetic parameters in LBC has been established.
format	article
author	Denis A. Ryabchikov Svetlana V. Chulkova Farhad A. Shamilov Nail V. Chanturia Sergey D. Zheltikov Nikolai N. Tupitsyn
author_facet	Denis A. Ryabchikov Svetlana V. Chulkova Farhad A. Shamilov Nail V. Chanturia Sergey D. Zheltikov Nikolai N. Tupitsyn
author_sort	Denis A. Ryabchikov
title	Breast cancer immunophenotype and its relationship with haematopoiesis
title_short	Breast cancer immunophenotype and its relationship with haematopoiesis
title_full	Breast cancer immunophenotype and its relationship with haematopoiesis
title_fullStr	Breast cancer immunophenotype and its relationship with haematopoiesis
title_full_unstemmed	Breast cancer immunophenotype and its relationship with haematopoiesis
title_sort	breast cancer immunophenotype and its relationship with haematopoiesis
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/a40f4ec5f398415db2bcda020a9a7bda
work_keys_str_mv	AT denisaryabchikov breastcancerimmunophenotypeanditsrelationshipwithhaematopoiesis AT svetlanavchulkova breastcancerimmunophenotypeanditsrelationshipwithhaematopoiesis AT farhadashamilov breastcancerimmunophenotypeanditsrelationshipwithhaematopoiesis AT nailvchanturia breastcancerimmunophenotypeanditsrelationshipwithhaematopoiesis AT sergeydzheltikov breastcancerimmunophenotypeanditsrelationshipwithhaematopoiesis AT nikolaintupitsyn breastcancerimmunophenotypeanditsrelationshipwithhaematopoiesis
_version_	1718406462693179392

Breast cancer immunophenotype and its relationship with haematopoiesis

Ejemplares similares